Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
US rare diseases focused biotech Quince Therapeutics today announced the online publication of data in The Lancet Neurology from its Phase III ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex. 15 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Acelyrin (Nasdaq: SLRN) has announced that its Phase III trial for izokibep in hidradenitis suppurativa (HS) met the primary endpoint, achieving a measure of efficacy at 12 weeks. 14 August 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Yselty (linzagolix) for the treatment of moderate to severe symptoms of uterine fibroids (UFs). 14 August 2024
Rivus Pharmaceuticals, a clinical-stage drug developer based in Virginia and California, announced that its Phase IIa HuMAIN trial met its primary endpoint of weight reduction. 14 August 2024
The National Institute for Health and Care Excellence (NICE) has published its final guidance recommending Accord Healthcare’s Orgovyx (relugolix) for the treatment of hormone-sensitive prostate cancer, recognizing the treatment as cost-effective in England. 14 August 2024
US oncology focused biotech Syros Pharmaceuticals announced that it will discontinue enrollment in the SELECT-AML-1 Phase II clinical trial. 14 August 2024
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Octapharma announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar (prothrombin complex concentrate, human-lans) have been published by the American peer-reviewed journal JAMA Network Open. 13 August 2024
Shares in Actinogen Medical, an Australian biotech developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, closed 58% lower on Monday. 13 August 2024
Connecticut, USA-based biotech start-up Halda Therapeutics announced that it has raised new financing of $126 million in a Series B extension. 13 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
German drug discovery company Evotec has announced the latest progress of its strategic partnership with US pharma major Bristol Myers Squibb relating to building a molecular glue-based pipeline. 13 August 2024
SpyBiotech, a UK biotech with a novel vaccine platform technology that can target infectious diseases, cancer and chronic diseases, has appointed Prakash Bhuyan as chief medical officer (CMO). 12 August 2024
The US Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults, from Ascendis Pharma. 12 August 2024
Californian genetic medicines company 4D Molecular Therapeutics is free to continue with its Phase I/II INGLAXA study for the gene therapy 4D-310 in Fabry disease cardiomyopathy. 12 August 2024
US ophthalmic drug developer Aldeyra Therapeutics saw its shares climb almost 22% to $5.10 on Friday, when it released new clinical trial data. 12 August 2024
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) on the new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults, submitted by US hallucinogenic medicines developer Lykos Therapeutics. 12 August 2024